Drugs / AD-209-1A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05631990 | Apr → Nov 2023 | essential hypertension | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-209-1A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05631990 ↗ |
| Route | Oral | “PO, Once daily(QD), 8weeks” NCT05631990 ↗ |